Jpmorgan Chase & CO Puma Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 17,994 shares of PBYI stock, worth $53,082. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,994
Previous 30,202
40.42%
Holding current value
$53,082
Previous $160,000
63.75%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PBYI
# of Institutions
101Shares Held
30.5MCall Options Held
73.5KPut Options Held
18.5K-
Vanguard Group Inc Valley Forge, PA3.6MShares$10.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.16MShares$9.33 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.03 Million0.59% of portfolio
-
Acadian Asset Management LLC Boston, MA1.95MShares$5.76 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $134M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...